What one share of Aura Biosciences holds
We are a clinical-stage biotechnology company developing precision therapies to treat solid tumors designed to preserve organ function. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with early choroidal melanoma (defined as small choroidal melanoma and/or indeterminate lesions) and is also in clinical development for other ocular oncology indications and bladder cancer.
Aura Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.78 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.40 |
| Cash and investments | $0.66 |
| Book value | $3.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$1.96 | $0.04 | −$1.86 | — | $5.18 |
| 2023 | — | −$1.93 | $0.02 | −$1.63 | — | $4.58 |
| 2024 | — | −$1.75 | $0.03 | −$1.63 | — | $3.04 |
| 2025 | — | −$1.76 | $0.01 | −$1.41 | — | $2.15 |
Common questions about Aura Biosciences
How much does one share of Aura Biosciences earn?
Over the last 12 months, Aura Biosciences lost $1.78 for each share.
Does Aura Biosciences pay a dividend?
Aura Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Aura Biosciences’s book value per share?
Aura Biosciences’s book value is $3.05 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Aura Biosciences have?
Each share of Aura Biosciences has $0.66 of cash and investments, as of June 30, 2026.
What is Aura Biosciences’s free cash flow per share?
−$1.40 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Aura Biosciences bought back shares?
Aura Biosciences’s share count rose about 102% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.